You are here

Vaccines

Primary tabs

Information on vaccines to counter Ebola and other diseases

The Mission of this group is to follow the development of vaccines and other medications to counter Ebola and other diseases.

Members

Kathy Gilbeaux mdmcdonald MDMcDonald_me_com mike kraft

Email address for group

vaccines_global@m.resiliencesystem.org

Sierra Leone: Mothers Refuse to Vaccinate Children for Fear of Resurgent Ebola

BREITBART.COM  by Frances Martel                                             June 16, 2015

Doctors in Port Loko, a northwestern region of Sierra Leone outside Freetown, are reporting a significant drop in the number of mothers bringing their children to hospitals for routine vaccinations. The mothers, they say, fear exposing their children to a resurgent Ebola virus, and in keeping them from hospitals are risking triggering the spread of polio or measles.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Ebola vaccines in limbo expose need for more speed in trials

REUTERS by Kate Keller and Ben Hirschler                                      June 17, 2015

LONDON --Drugmakers' plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa.

GlaxoSmithKline, Merck and Johnson & Johnson are struggling to recruit volunteers with enough exposure to the disease to prove whether their vaccines are doing the job and preventing infection.

The story might have been very different with just another three or four months of disease spread, underscoring the need to act more quickly to develop vaccines for emerging diseases....

Guinea, where Ebola is still infecting new victims, as "the only hope" for showing efficacy, according to Kieny and to Adrian Hill, director of the Jenner Institute at Britain's Oxford University.

The WHO is overseeing the so-called ring vaccination study in Guinea in which close contacts and family around each new case of Ebola are vaccinated -- either immediately or after a three-week delay -- to see if the shot offers protection.

Read complete story.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Favipiravir—a prophylactic treatment for Ebola contacts?

THE LANCET byMichel Van Herp, Hilde Declerck and Tom Decroo June 13, 2015

.. the efficacy of candidate Ebola vaccines for primary prevention has not been proven.2 Furthermore, in communities in which Ebola transmission might be ongoing, an important question is: how will such a vaccination be perceived if a vaccinated person develops Ebola? Such a scenario is possible in people who contract Ebola virus before vaccination. If a person is infected with Ebola virus before vaccination, the vaccine might have a post-exposure prophylactic effect. However, how effective this prophylaxis might be is unknown.2 Moreover, if someone is infected more than 48 h before vaccination, the post-exposure prophylactic effect is likely to be insufficient, leading to possible development of Ebola after vaccination. This scenario is likely to result in serious issues relating to community trust and acceptance of an Ebola vaccine.3 How to exclude Ebola among people presenting with post-vaccination fever is also an issue.2

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

How close is the Ebola vaccine?

PUBLIC BROADCASTING CORP by Caleb Hellerman         June 11, 2015

The quest for an Ebola vaccine has been a journey filled with excruciating delays and mad dashes. The latest outbreak in West Africa caused governments and drug companies to jumpstart research that had languished back when the threat of Ebola wasn’t big enough to sustain a commercial market. (Prior to 2013, the virus had sickened fewer than 2,300 people in known history). Human safety trials of two vaccines began last summer — each being given to a small group of healthy volunteers. When no major side effects were apparent, health officials scrambled to launch larger tests in the countries that were most affected by Ebola.

A volunteer receives an Ebola vaccine in Sierra Leone. Thousands of these voluntary immunizations have been tested so far in the West African nation. Photo by Cameron Hickey.

Problem, Solution, SitRep, or ?: 

A Chinese Ebola Drug Raises Hopes, and Rancor

NEW YORK TIMES   by Sheri Fink, MD                                                      June 12, 2015   

After a nurse who contracted Ebola in Sierra Leone was discharged Wednesday from a Rome hospital, a doctor there described the experimental treatments the patient had received as “absolutely miraculous.”

The lab at Beijing Mabworks, which developed the experimental drug, MIL77, used to treat Ebola. Credit Adam Dean for The New York Times

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ghana halts Ebola vaccine trial due to community protests

REUTERS                                             June 10, 2015

ACCRA - Ghana has halted a plan to test two Ebola vaccines in an eastern town after legislators backed local protests against the trials sparked by fears of contamination, officials said on Wednesday.

The country's Food and Drugs Authority said it had begun enlisting volunteers in Hohoe in the Volta region to be injected with drugs made by Johnson & Johnson and Bavarian Nordic as part of a global Ebola vaccine drive.

Youth leaders threatened to boycott the program. "We don't want to be guinea pigs," one local leader told Reuters.

The (health) minister has suspended the trials indefinitely because the people said they don't want it," Health Ministry spokesman Tony Goodman said.

Read complete article.

http://news.yahoo.com/ghana-halts-ebola-vaccine-trial-due-community-protests-230206801--finance.html;_ylt=AwrC1Cj8y3hVjHUAonXQtDMD;_ylu=X3oDMTByOHZyb21tBGNvbG8DYmYxBHBvcwMxBHZ0aWQDBHNlYwNzcg--

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

NIH Study Finds No Evidence of Accelerated Ebola Virus Evolution in West Africa

NIH Institute of Allergy and Infectious Diseases (NIAID)                            June 9, 2015

According to a recent report from the National Institutes of Health (NIH), the current strain of the Ebola virus that is circulating through West Africa is called the Makona strain and is less aggressive than the original Mayinga strain that, which was isolated in Central Africa in 1976.
When compared to the Mayinga strain, the Makona strain takes approximately two additional days to start terminal disease in an animal subject. This is an important discovery to scientists, as they wonder whether the Ebola strain in West Africa will grow more severe over time.

The test subjects were cynomolgus macaques. Researchers used these animals to model disease and infection in humans. The scientists infected three macaques with the Mayinga strain from 1976 and an additional three with the Makona strain from 2015.

 
 Ebola virus, isolated in November 2014 from patient blood samples obtained in Mali. The virus was isolated on Vero cells in a BSL-4 suite at Rocky Mountain Laboratories.
Credit: NIAID RML

Read complete story.

Problem, Solution, SitRep, or ?: 

Vaccination teams defeat 'Ebola effect' in Guinea

IRIN  by By Jennifer Lazuta                            April 29, 2015
GUECKEDOU,Guinea  - The odds were stacked against Guinea's vaccination teams. The initial side effects of the measles vaccine can easily be mistaken for the first symptoms of hemorraghic fever and a false rumour had spread blaming the distribution of deworming pills in late 2013 for bringing Ebola into the country.

A child receives a shot of measles vaccine Photo: Jennifer Lazuta/IRIN

But thanks to an exhaustive door-to-door effort, promoting the benefits of the vaccine and dispelling myths about Ebola, nearly 100,000 children between the ages of six months and 10 years in Guinea’s southeastern Gueckedou region are now protected against the highly contagious measles virus.

Local communities were understandably suspicious of health workers and Western medicine, but many of them were open to persuasion, so health teams went around from village to village, talking to families and trying to ease their concerns.

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ella Foundation announces key outcomes in Ebola vaccine research

BUSINESS STANDARD                                                                        April 27, 2015

HYDERABAD, India --Ella Foundation, which has taken up research for finding a potential vaccine for the deadly Ebola virus, today said it had successfully completed preliminary studies on the virus, which was responsible for high fatalities among humans in central Africa.

The Hyderabad-based foundation said it had completed the preliminary animal (with mice) experiments of the virus' glycoprotein with the targeted adenovirus, and the "immune response results have been good", which would be followed by toxicology tests and the subsequent clinical trials involving human beings.

Adenoviruses are responsible for respiratory infections, gastroenteritis, cystitis, and primary pneumonia in humans, and are therefore used as a clear target to understand the human immunity characteristics in laboratory. However, the efficacy of the vaccine is judged by the outcomes seen in human trials.

Read complete story.

http://www.business-standard.com/article/current-affairs/ella-foundation-announces-key-outcomes-in-ebola-vaccine-research-115042700631_1.html

Problem, Solution, SitRep, or ?: 

Evaluating Clinical Trial Designs for Investigational Treatments of Ebola Virus Disease

PLOS MEDICINE   by Ben Cooper and others                                                             April 14, 2015
Experimental treatments for Ebola virus disease might reduce EVD mortality. There is uncertainty about the ability of different clinical trial designs to identify effective treatments, and about the feasibility of implementing individually randomised controlled trials during an Ebola epidemic

A treatment evaluation programme for use in EVD was devised using a multi-stage approach (MSA) with two or three stages, including both non-randomised and randomised elements. The probabilities of rightly or wrongly recommending the experimental treatment, the required sample size, and the consequences for epidemic outcomes over 100 d under two epidemic scenarios were compared for the MSA, a sequential randomised controlled trial (SRCT) with up to 20 interim analyses, and, as a reference case, a conventional randomised controlled trial (RCT) without interim analyses.

Read complete study.

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001815

Problem, Solution, SitRep, or ?: 

Pages

howdy folks
Page loaded in 0.888 seconds.